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Background/aim: The aim of this study was to document the effect of the application of prophylactic central compartment dissection
on radioiodine ablation activities for papillary thyroid carcinoma.
Materials and methods: This retrospective study included 452 (383 females, 69 males; mean age = 46.69 years, min–max: 13–71) patients
who received ablative radioiodine activity between April 2010 and December 2014. The histopathological reports of thyroidectomy and
the administered radioiodine activity were evaluated. Frequencies of prophylactic central compartment dissection according to T stage
of the primary tumor, detection rate of lymph node metastases, and its effect on radioiodine ablation activities were calculated.
Results: Prophylactic central compartment dissection was applied for a total of 252 (56%) patients. The T stages of these patients were
T1a, T1b, T2, and T3 in 85 (34%), 106 (42%), 41 (16%), and 20 (8%) cases, respectively. The administered radioiodine ablation activity
was affected by central compartment lymph node metastases in 112 (44%) patients. While 32 (29%) of these patients had papillary
microcarcinoma (T1a), 48 (43%), 20 (18%), and 12 (11%) of them had T1b, T2, and T3 tumors, respectively.
Conclusion: The application of prophylactic central compartment dissection affects the radioiodine ablation activity in approximately
half of patients. This effect is more prominent in T1 stage tumors.
Key words: Papillary thyroid carcinoma, radioiodine ablation treatment, prophylactic central compartment dissection

1. Introduction
Papillary thyroid carcinoma (PTC) is the most common
thyroid cancer and accounts for more than 80% of
thyroid carcinomas (1–3). The extent of surgery in PTC
patients who do not have clinically suspect lymph nodes
(cN0) remains controversial. Despite the good longterm outcome of PTCs, approximately 50% of patients
have cervical lymph node metastasis (1,4). The presence
of lymph node metastasis is associated with a high
locoregional recurrence rate (2,5). However, according to
current concepts, there is no evidence of improvement in
survival after prophylactic central compartment dissection
(PCLND) despite the high rate of occult lymph node
metastasis (6–8). In contrast, a large nested case-control
study revealed that patients with lymph node metastasis
have a higher mortality rate and that incomplete surgery is
one of the most important factors in increasing mortality
(9).
From the aspect of nuclear medicine, there is an element
of safety in knowing the central compartment status
when evaluating the need for radioiodine (RAI) ablation
* Correspondence: csoydal@yahoo.com
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treatment and calculating RAI activities. Preablative
thyroglobulin (Tg) levels may be misleading due to the
presence of different amounts of residual thyroid tissue.
In addition, ultrasonographic evaluation of the central
compartment becomes more difficult after thyroidectomy.
Therefore, the present study was planned to document
the effect of the application of PCLND on RAI ablation
activities for papillary thyroid carcinoma.
2. Material and Method
2.1. Patients
A retrospective review was conducted of the descriptive
and clinical follow-up data of 568 patients who were
referred to our department for RAI ablation treatment
between April 2010 and December 2014. Ten patients
with a diagnosis of follicular thyroid carcinoma and
106 patients with suspected lymph nodes during the
preoperative evaluations were excluded from the analysis.
All of the 452 patients included had undergone total or
near-total thyroidectomy following neck ultrasound and
fine-needle aspiration biopsy. None of the patients had
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any suspicious lymph nodes in the central or lateral neck
compartments. As there were no indications for routine
central compartment lymph node dissection in any
patient, PCLND was applied to only 252 of the total 452
patients according to the surgeon’s preference.
2.2. Radioiodine ablation treatment
Indications for RAI ablation treatments were evaluated and
treatment was administered according to our routine fixed
activity protocol if it was indicated. The given activities
were in the range of 30–100 mCi for intrathyroidal
tumors and 125–150 mCi for lymph node metastases.
After RAI treatment, patients were hospitalized according
to national regulations. Pinhole neck and parallel-hole
whole-body scintigraphic images were obtained 6–8 days
after treatment to evaluate residual tissue and possible
metastases.
2.3. Data and statistical analysis
Descriptive features, surgical procedures, postoperative
pathological examinations, and the given radioactive
iodine activities were noted for statistical analysis. The
application of PCLND and its effect on the administered
RAI activities were calculated according to the T stage
of tumors. Comparisons were made of sex, age, tumor
dimension, capsule invasion, and preablative Tg and antiTg levels of patients with (Group 1) and without (Group
2) PCLND.

3. Results
PCLND was applied to 252 (56%) of the 452 patients,
comprising 383 females and 69 males with a mean age
of 46.69 years (min–max: 13–71 years). The T stages of
these patients were T1a, T1b, T2, and T3 in 85 (34%), 106
(42%), 41 (16%), and 20 (8%), respectively. There was no
statistically significant difference between the sex, mean
age, tumor dimension, or preablative Tg and anti-Tg
levels of patients who underwent central compartment
dissection and those who did not. A statistically significant
difference was determined between the groups for thyroid
capsule invasion rates (25% vs. 14%, P = 0.001) (Table 1).
Central compartment lymph node metastasis was
detected in 112 (44%) of the 252 patients, thereby affecting
the given RAI ablation doses. While 32 (29%) of these
patients had papillary microcarcinoma (T1a), 48 (43%),
20 (18%), and 12 (11%) had T1b, T2, and T3 tumors,
respectively. There was no significant difference in sex,
mean age, or preablative Tg and anti-Tg levels between
the patients with and without central compartment
lymph node metastasis, while a significant difference was
determined in mean tumor dimension (1.72 vs. 1.38 cm, P
= 0.03) and thyroid capsule invasion rate (10% vs. 42%, P
= 0.001) (Table 2).

Table 1. Difference between groups of patients with and without PCLND.
CLN metastasis
Age (mean years)
Sex (F/M)
Tumor dimension (mean)
Thyroid capsule invasion
Preablative Tg (mean)
Preablative anti-Tg (mean)

P-value

Positive

46.7

Negative

53.6

Positive

225/37

Negative

160/32

Positive

1.68

Negative

1.55

Positive

25%

Negative

14%

Positive

8.84

Negative

7.87

Positive

18.12

Negative

10.57

0.18
0.87
0.82
<0.01
0.50
0.17

PCLND: Prophylactic central lymph node dissection, F: female, M: male, Tg: thyroglobulin, anti-Tg:
antithyroglobulin.
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Table 2. Difference between groups of patients with and without CLN metastasis.
CLN metastasis
Age (mean years)
Sex (F/M)
Tumor dimension (mean)
Thyroid capsule invasion
Preablative Tg (mean)
Preablative anti-Tg (mean)

P-value

Positive

47.1

Negative

59.6

Positive

124/5

Negative

120/3

Positive

1.72

Negative

1.38

Positive

42%

Negative

10%

Positive

6.36

Negative

11.35

Positive

24.32

Negative

12.02

0.32
0.05
0.03
<0.01
0.90
0.18

CLN: Central lymph node, F: female, M: male, Tg: thyroglobulin, anti-Tg: antithyroglobulin.

4. Discussion
Although central lymph node dissection is recommended
for cN1 patients, the need for PCLND in cN0 PTC patients
is still controversial (10–15). Generally, it is accepted
that lymph node metastasis is associated with higher
locoregional recurrence and distant metastasis rates.
However, it does not affect survival (16). In contrast, a
large-scale nested case-control study revealed that patients
with lymph node metastasis experience higher mortality.
Moreover, incomplete surgical excision is associated with
higher mortality, particularly in Stage 1 patients (9).
Some surgeons do not prefer PCLND for cN0 patients
due to morbidities related to recurrent nerve paralysis and
hypoparathyroidism. However, others claim that because
there could be lymph node metastasis, even in low-risk
patients, and reoperation in this compartment is technically
difficult, PCLND should be applied. Practice guidelines
on this topic are also conflicting. While the American
Thyroid Association guidelines suggest that PCLND can
be considered for patients with advanced primary tumors
(T3 and T4), the National Comprehensive Cancer Network
guidelines recommend PCLND for cN0 patients at any
stage of primary tumors (category 2B) (17,18).
Therefore, the outcome of applying PCLND or not has
been a subject of interest for several authors. Calo et al.
researched whether or not total thyroidectomy without
PCLND in cN0 patients was adequate and concluded
that total thyroidectomy appeared to be adequate for cN0
patients. However, PCLND could be recommended for
high-risk patients as a more appropriate selection for RAI
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treatment (19). In a large series, Jiang et al. investigated
the clinical characteristics related to central lymph node
metastasis in 916 cN0 PTC patients. Tumors located in the
upper/middle pole/whole lobe, patient age of ≤35 years,
tumor size of >1.5 cm, and capsule invasion were found
to be risk factors of central lymph node metastasis (20).
From another aspect, Liu et al. investigated the longterm outcome of the observation of cN0 PTC patients.
They concluded that observation without PCLND was
safe for this patient group, particularly for those without
extrathyroidal invasion (6).
In the current series, PCLND was applied to 252
of the 452 patients. Most of the patients (76%) who
underwent PCLND had T1 stage tumors. As the expected
macroscopic lymph node metastasis rate is higher in T2
and T3 tumors than T1 tumors, the therapeutic central
compartment dissection indication rate in T2 and T3
tumors might be higher. Therefore, a large proportion of
patients with a history of PCLND might have T1 tumors.
The only significant difference between the group to which
PCLND was applied and the group to which it was not
was in the thyroid capsule invasion rates (25% and 14%).
PCLND in cN0 patients might be an intraoperative choice
of surgeons, depending on the location of the tumor and
the appearance of the thyroid capsule and lymph nodes.
At least some patients with thyroid capsule invasion could
have had PCLND applied due to macroscopic suspicion
of extrathyroidal invasion during the intraoperative
observation.
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Central lymph node metastasis was detected in 112 of
the 252 patients and the need for RAI ablation or the given
RAI ablation dose was affected by this in all cases. The
most important result of this analysis is that the majority of
those patients had T1 tumors. Moreover, 29% of that group
consisted of patients with papillary microcarcinoma (T1a)
who did not have any RAI ablation indication when there
was no central lymph node metastasis. Another important
finding was the significance in mean tumor dimension and
capsule invasion rates of patients with and without central
lymph node metastasis. These data support the results of
previous studies (3,12). Although the difference between
mean tumor dimensions was determined to be statistically
significant, in clinical practice it is not significant as the
mean values were close (1.72 vs. 1.38 cm). However,
thyroidal capsule invasion might be more significant.

Preoperative detailed evaluation by an experienced hand
of the thyroid gland and central/lateral lymph node
compartments is of great importance, especially the careful
inspection of the primary tumor and its contact with the
thyroid capsule and the integrity of the capsule.
In this study, an analysis was made of the effect of
the application of PCLND on RAI decision and dose.
However, no evaluation could be made of the long-term
effect of the presence of lymph node metastasis or the
application of RAI ablation treatment. We preferred to
report the early results of this series as we think that they
could be of greater importance, but we also plan to analyze
long-term follow-up data.
In conclusion, the application of PCLND affects the
RAI ablation dose in approximately half of patients. This
effect becomes more prominent in T1 stage tumors.
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